Novartis Fights Enhanced Damages Bid After $178M Jury Loss
By Adam Lidgett · November 3, 2021, 6:15 PM EDT
Novartis says that it shouldn't have to pay enhanced damages after a jury hit the company with a $177.8 million verdict for selling a skin cancer drug that infringes two patents...
To view the full article, register now.